Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $196 million, an increase of approximately $1 million compared to the prior year [20] - Prescription transaction revenue decreased by 9% year-over-year, primarily due to the impact of Rite Aid store closures and lower transaction volume in the integrated savings program [21] - Adjusted EBITDA for the quarter was $66.3 million, reflecting a 2% increase year-over-year and an adjusted EBITDA margin of 33.8%, which is an improvement of 50 basis points compared to the prior year [22] Business Line Data and Key Metrics Changes - Manufacturer solutions revenue grew by 54% year-over-year to $43.4 million, driven by strong execution and expansion across new and existing brand partnerships [21][11] - The company has over 200 brand affordability programs on its platform, with nearly 80 offering cash prices [13] Market Data and Key Metrics Changes - The ongoing changes in the U.S. healthcare environment, particularly around prescription drug pricing, are seen as a significant opportunity for GoodRx, especially with the introduction of Trump Rx and the focus on price transparency [6][9] - The company is positioned to benefit from the anticipated increase in uninsured individuals and higher out-of-pocket costs due to changes in the Affordable Care Act marketplace subsidies and Medicaid support [9] Company Strategy and Development Direction - GoodRx is focused on expanding partnerships with pharmaceutical manufacturers and retail pharmacies to enhance access and affordability for consumers [19] - The company is investing in its manufacturer solutions capabilities and aims to deliver a true end-to-end e-commerce model to the pharmaceutical industry [14] - The new brand campaign, "The Savings Wrangler," aims to reinforce GoodRx's position as a trusted name in prescription savings and has already shown positive results in key marketing metrics [18] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the broader healthcare environment's challenges but remains confident in GoodRx's ability to navigate these changes and capitalize on emerging opportunities [10][25] - The company expects continued growth in its manufacturer solutions segment, projecting approximately 35% revenue growth in 2025 [24] - Management is optimistic about the long-term growth potential as the market shifts towards greater price transparency and consumer-direct models [9][26] Other Important Information - The company repurchased approximately 13.4 million shares at an average price of $4.61 per share, totaling $61.6 million, with about $81.4 million remaining under its share repurchase program [22] - GoodRx is actively engaged with the administration and HHS to inform policy efforts that expand access and affordability for all Americans [6] Q&A Session Summary Question: Can you discuss the stabilizing PTR environment and its implications for GoodRx? - Management noted that 2025 has been challenging due to various macro conditions but anticipates a return to growth in 2026 as more people may become uninsured, creating a tailwind for GoodRx [30][31] Question: How does GoodRx differentiate itself in the manufacturer solutions space? - GoodRx highlighted its position as the number one digital prescription marketplace, providing manufacturers with significant ROI and access to a large consumer base [33] Question: What are the implications of PBMs moving towards point-of-sale discounts? - Management expressed support for this shift, indicating that it aligns with GoodRx's mission of enhancing affordability for consumers at the pharmacy counter [36][37] Question: How will GoodRx integrate with Trump Rx? - GoodRx is actively working with HHS to integrate its pricing into the Trump Rx platform, positioning itself as a key provider of pricing information [39][41] Question: What is the outlook for the ISP relationship and potential new products? - Management indicated that while the ISP relationship has evolved, there remains potential for new product offerings that could enhance affordability for consumers [43][44]

Core Insights - Hydreight Technologies Inc. has reported significant growth in its financial performance for the fiscal year 2024, achieving record revenues and positive Adjusted EBITDA, while focusing on scaling its VSDHOne platform for 2025 [2][6][9]. Financial Performance - The company achieved record topline revenue of CAD 22.32 million in 2024, representing a 31% increase from 2023 [6][17]. - GAAP revenue for 2024 was CAD 16.04 million, up 39% from CAD 11.51 million in 2023 [6][9]. - Adjusted EBITDA for 2024 was CAD 490,000, a turnaround from a loss of CAD 1.38 million in 2023 [6][17]. - The gross margin for 2024 was CAD 5.75 million, an increase of 8% from the previous year [6][17]. - The fourth quarter of 2024 saw revenues of CAD 4.04 million, a 20% increase compared to the same quarter in 2023 [7][9]. Strategic Focus for 2025 - The company plans to expand franchise white-label partnerships to enhance its market presence [13]. - There is a focus on increasing pharmacy margins through supply chain optimization and strategic pricing [14]. - New wellness categories will be launched, including NAD+, testosterone replacement therapy, and peptide therapies [14]. - The onboarding of high-growth D2C healthcare companies on the VSDHOne platform will be accelerated [15]. - The company aims to attract and support more licensed nurses to enhance its provider network [15]. - Strategic tuck-in acquisitions of complementary D2C health brands are being pursued to improve product mix and margins [15]. Recognition and Milestones - Hydreight was ranked 9 on Deloitte's 2024 Technology Fast 50 list and 56 on the Technology Fast 500 list for North America [6][9]. - The company completed its first post-IPO financing, raising CAD 5.4 million in February 2025 to support its growth initiatives [6][9]. Operational Highlights - The company operates a network of over 3,000 nurses and 200+ physicians across all 50 states, facilitating a scalable telehealth and at-home care model [11][12]. - Hydreight's VSDHOne platform supports over 400 Direct to Consumer license holders, enabling rapid entry into the online healthcare space [11][21].